Friday, April 29, 2016
Xarelto (Rivaroxaban) May Cause Life-Threatening Bleeds
Approved by the FDA in 2011, Xarelto is one of the newest anticoagulants on the market. Xarelto is a prescription medication used to reduce the risk of stroke and blood clots in people with non-valvular atrial fibrillation. It is also used to treat and prevent deep vein thrombosis and pulmonary embolism, in particular in patients who have recently had knee or hip replacement surgery.
Xarelto, which is manufactured and marketed by Bayer and Janssen Pharmaceuticals, is an alternative to Coumadin (warfarin). Unlike Coumadin, however, there is no approved antidote to quickly reverse the blood-thinning effects of Xarelto. For this reason, Xarelto may substantially increase the risk of severe and uncontrollable bleeds, which may result in serious injury and death.
Individuals who were prescribed Xarelto and suffered severe bleeding have filed lawsuits against the drug’s manufacturers. In January 2015, a mass tort program was created in the Philadelphia Court of Common Pleas. To date, over 700 lawsuits have been filed in Philadelphia, and approximately 5,000 Xarelto lawsuits have been filed in MDL 2592 in the U.S. District Court for the Eastern District of Louisiana.